Linked Data API

Show Search Form

Search Results

1132764
registered interest false more like this
date less than 2019-06-18more like thismore than 2019-06-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text What progress the Government has made on making medical cannabis available to people who need it. more like this
tabling member constituency Gower more like this
tabling member printed
Tonia Antoniazzi more like this
uin 911421 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-18more like thismore than 2019-06-18
answer text <p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.</p><p /><p /> more like this
answering member constituency West Suffolk more like this
answering member printed Matt Hancock more like this
question first answered
less than 2019-06-18T16:50:49.883Zmore like thismore than 2019-06-18T16:50:49.883Z
answering member
4070
label Biography information for Matt Hancock more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this
1136901
registered interest false more like this
date less than 2019-07-04more like thismore than 2019-07-04
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals on a regulatory category medicinal cannabis. more like this
tabling member constituency Birkenhead more like this
tabling member printed
Frank Field more like this
uin 273329 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-09more like thismore than 2019-07-09
answer text <p>Legislation on cannabis for medicinal use has already been passed. The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s Specialist Register to prescribe unlicensed cannabis-based products for medicinal use, where it is clinically appropriate and in the best interest of patients.</p><p>The regulations use the existing regulatory frameworks for medicines and the misuse of drugs, an approach which the Government believes is proportionate and evidence-based, ensuring that clinicians can access these products whilst minimising the risk of misuse, harm and diversion.</p><p>Applications can also continue to be made to the Medicines and Healthcare products Regulatory Agency by any company wishing to market their product as a licensed medicine.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-09T16:03:02.317Zmore like thismore than 2019-07-09T16:03:02.317Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
478
label Biography information for Frank Field more like this
1135314
registered interest false more like this
date less than 2019-06-27more like thismore than 2019-06-27
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 27 June 2019 to Question 266815 on Cannabis: Medical Treatments, how many prescriptions for the use of medicinal cannabis were issued in each of the last 12 months for which data is available. more like this
tabling member constituency Burton more like this
tabling member printed
Andrew Griffiths more like this
uin 270334 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-02more like thismore than 2019-07-02
answer text <p>NHS England and NHS Improvement are using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England and NHS Improvement Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p>The NHS Business Services Authority is only able to provide information on prescriptions for cannabis-based medicines that have been dispensed and submitted to the NHS Business Services Authority. The NHS Business Services Authority does not hold information on prescriptions for cannabis-based medicines which have been issued but not fulfilled.</p><p>The following table shows the number of items for Nabilone and Sativex (licensed cannabis-based medicines) and unlicensed cannabis-based medicines that were prescribed on an NHS prescription, dispensed in the community and submitted to the NHS Business Services Authority for reimbursement since May 2018.</p><table><tbody><tr><td><p>Month</p></td><td><p>Nabilone</p></td><td><p>Sativex</p></td><td><p>Unlicensed cannabis-based medicines</p></td></tr><tr><td><p>May 2018</p></td><td><p>45</p></td><td><p>183</p></td><td><p> </p></td></tr><tr><td><p>June 2018</p></td><td><p>42</p></td><td><p>157</p></td><td><p> </p></td></tr><tr><td><p>July 2018</p></td><td><p>48</p></td><td><p>170</p></td><td><p>2*</p></td></tr><tr><td><p>August 2018</p></td><td><p>54</p></td><td><p>161</p></td><td><p> </p></td></tr><tr><td><p>September 2018</p></td><td><p>45</p></td><td><p>172</p></td><td><p>1*</p></td></tr><tr><td><p>October 2018</p></td><td><p>50</p></td><td><p>164</p></td><td><p> </p></td></tr><tr><td><p>November 2018</p></td><td><p>46</p></td><td><p>175</p></td><td><p>2</p></td></tr><tr><td><p>December 2018</p></td><td><p>49</p></td><td><p>181</p></td><td><p>1</p></td></tr><tr><td><p>January 2019</p></td><td><p>44</p></td><td><p>167</p></td><td><p>2</p></td></tr><tr><td><p>February 2019</p></td><td><p>36</p></td><td><p>159</p></td><td><p>1</p></td></tr><tr><td><p>March 2019</p></td><td><p>51</p></td><td><p>171</p></td><td><p>2</p></td></tr><tr><td><p>April 2019</p></td><td><p>49</p></td><td><p>156</p></td><td><p>0</p></td></tr><tr><td><p>May 2019</p></td><td><p>Data not yet available</p></td><td><p>Data not yet available</p></td><td><p>2</p></td></tr></tbody></table><p>Note: * These figures represent prescribing of unlicensed cannabis-based medicines imported on a Home Office licence.</p><p>The following table shows the same products listed above covering the same time period but this data relates to private prescribing on an FP10PCD where the forms have been submitted to the NHS Business Services Authority for reporting and monitoring purposes only.</p><table><tbody><tr><td><p>Month</p></td><td><p>Nabilone</p></td><td><p>Sativex</p></td><td><p>Epidiolex</p></td><td><p>Unlicensed cannabis-based medicines</p></td></tr><tr><td><p>May 2018</p></td><td><p>0</p></td><td><p>1</p></td><td><p>0</p></td><td><p> </p></td></tr><tr><td><p>Jun 2018</p></td><td><p>0</p></td><td><p>3</p></td><td><p>0</p></td><td><p> </p></td></tr><tr><td><p>July 2018</p></td><td><p>0</p></td><td><p>2</p></td><td><p>0</p></td><td><p> </p></td></tr><tr><td><p>August 2018</p></td><td><p>0</p></td><td><p>1</p></td><td><p>0</p></td><td><p> </p></td></tr><tr><td><p>September 2018</p></td><td><p>0</p></td><td><p>3</p></td><td><p>0</p></td><td><p> </p></td></tr><tr><td><p>October 2018</p></td><td><p>0</p></td><td><p>3</p></td><td><p>0</p></td><td><p> </p></td></tr><tr><td><p>November 2018</p></td><td><p>0</p></td><td><p>1</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>December 2018</p></td><td><p>0</p></td><td><p>6</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>January 2019</p></td><td><p>0</p></td><td><p>5</p></td><td><p>0</p></td><td><p>4</p></td></tr><tr><td><p>February 2019</p></td><td><p>0</p></td><td><p>3</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td><p>March 2019</p></td><td><p>0</p></td><td><p>3</p></td><td><p>0</p></td><td><p>3</p></td></tr><tr><td><p>April 2019</p></td><td><p>1</p></td><td><p>2</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>May 2019</p></td><td><p>Data not yet available</p></td><td><p>Data not yet available</p></td><td><p>Data not yet available</p></td><td><p>1</p></td></tr></tbody></table><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p>Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that, up until the end of March 2019, five patients have had private prescriptions issued for a cannabis-based product for medicinal use in independent secondary/tertiary care in England.</p><p>145 patients have accessed Epidiolex though GW Pharma’s early access programmes ahead of a licensing decision by the European Medicines Agency.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-07-02T16:26:39.453Zmore like thismore than 2019-07-02T16:26:39.453Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
3936
label Biography information for Andrew Griffiths more like this
1133167
registered interest false more like this
date less than 2019-06-19more like thismore than 2019-06-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products. more like this
tabling member constituency Gower more like this
tabling member printed
Tonia Antoniazzi more like this
uin 266862 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-27more like thismore than 2019-06-27
answer text <p>The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.</p><p>Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.</p><p>NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-27T12:43:17.543Zmore like thismore than 2019-06-27T12:43:17.543Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this
1133166
registered interest false more like this
date less than 2019-06-19more like thismore than 2019-06-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision. more like this
tabling member constituency Gower more like this
tabling member printed
Tonia Antoniazzi more like this
uin 266861 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-27more like thismore than 2019-06-27
answer text <p>In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-27T12:42:09.417Zmore like thismore than 2019-06-27T12:42:09.417Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4623
label Biography information for Tonia Antoniazzi more like this
1133326
registered interest false more like this
date less than 2019-06-19more like thismore than 2019-06-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many licences have been issued for the prescription of medicinal cannabis. more like this
tabling member constituency Burton more like this
tabling member printed
Andrew Griffiths more like this
uin 266815 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-27more like thismore than 2019-06-27
answer text <p>The law stipulates that any doctor on the General Medical Council’s Specialist Register can prescribe cannabis-based products for medicinal use. No licences are required to prescribe.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-27T12:40:10.313Zmore like thismore than 2019-06-27T12:40:10.313Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
3936
label Biography information for Andrew Griffiths more like this
1132025
registered interest false more like this
date less than 2019-06-13more like thismore than 2019-06-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how and by whom medical cannabis was produced in the UK before its legalisation. more like this
tabling member constituency Central Ayrshire more like this
tabling member printed
Dr Philippa Whitford more like this
uin 264425 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-18more like thismore than 2019-06-18
answer text <p>Prior to the change of the law on 1 November 2018, only cannabis-based products that had been given a marketing authorisation (product licence) by the medicines regulators, the Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency could be prescribed. Before issuing a marketing authorisation the MHRA accesses all the available evidence on efficacy and safety arising out of pre-clinical research and clinical trials and evidence and information supplied by the manufacturer. The regulators also inspect the factory where the medicine is to be made, to make sure that supplies will be of a uniformly and consistently high standard.</p><p> </p><p>The following cannabis-based products and related products received a marketing authorisation in the United Kingdom/European Union before 1 November 2018:</p><p> </p><p>- Sativex - (produced by GW Pharmaceuticals) containing tetrahydrocannabinol (THC) and cannabidiol - holds a licence for spasticity in multiple sclerosis; and</p><p>- Nabilone - (multiple manufacturers) which contains a synthetic, non-natural cannabinoid which mimics THC, holds a marketing authorisation for nausea and vomiting caused by chemotherapy.</p><p> </p><p>In addition, Epidiolex (also produced by GW Pharmaceuticals from cannabis) for two severe forms of intractable epilepsy (Lennox-Gastaut Syndrome or Dravet Syndrome), is currently being considered for a marketing authorisation by the European Medicines Agency.</p><p> </p><p>The change in the law allows the prescription, by specialist doctors on the General Medical Council’s Specialist Register, of cannabis-based products that have not been through this rigorous process but that meet certain quality standards in cases where all licensed products have been considered and discounted and it is in the best interest of the patient. It also makes</p><p>it easier and will incentivise further research into the potential health benefits of cannabis-based products and the development of further licensed products for more routine use in the health service.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-18T16:31:54.17Zmore like thismore than 2019-06-18T16:31:54.17Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4385
label Biography information for Dr Philippa Whitford more like this
1131293
registered interest false more like this
date less than 2019-06-11more like thismore than 2019-06-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many companies are licensed to sell cannabis products to the NHS. more like this
tabling member constituency Ross, Skye and Lochaber more like this
tabling member printed
Ian Blackford more like this
uin 263171 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-19more like thismore than 2019-06-19
answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p> </p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and non-objection to import from the MHRA for each individual import of a controlled drug.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-19T09:39:54.803Zmore like thismore than 2019-06-19T09:39:54.803Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4390
label Biography information for Ian Blackford more like this
1131321
registered interest false more like this
date less than 2019-06-11more like thismore than 2019-06-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what progress he has made on ensuring that medical cannabis is available to people who need it. more like this
tabling member constituency Birkenhead more like this
tabling member printed
Frank Field more like this
uin 263063 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-19more like thismore than 2019-06-19
answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients.</p><p>Interim clinical guidance has been issued by the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists to support doctors looking to prescribe cannabis-based products. The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of cannabis-based medicinal products, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-19T14:21:18.483Zmore like thismore than 2019-06-19T14:21:18.483Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
478
label Biography information for Frank Field more like this
1129369
registered interest false more like this
date less than 2019-06-03more like thismore than 2019-06-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what discussions his Department has had with (a) NHS England, (b) manufacturers and (c) NICE on funding arrangements for accessing (a) licensed and (b) unlicensed cannabis-based medicines on the NHS. more like this
tabling member constituency Dudley North more like this
tabling member printed
Ian Austin more like this
uin 259109 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-11more like thismore than 2019-06-11
answer text <p>In developing policy on the rescheduling of cannabis-based products for medicinal use, the Government has applied existing arrangements for accessing licensed and unlicensed medicines on the National Health Service. The Department has not had discussions with NHS England, manufacturers or the National Institute for Health and Care Excellence (NICE) on funding arrangements for accessing licensed or unlicensed cannabis-based products, beyond the existing arrangements.</p><p>The recent changes to the law to reschedule cannabis-based products for medicinal use, does not impact on the availability of existing licensed cannabis-based medicinal products, such as Sativex and Nabilone. Any medicines which receive a marketing authorisation from the Medicines and Healthcare products Regulatory Agency or European Medicines Agency will be assessed for cost effectiveness by NICE. This is the foundation of NHS decisions about routine funding, and applies to all licensed medicines.</p><p>For unlicensed medicines, the normal NHS medicines governance systems apply, as they do to all locally funded unlicensed treatments. These processes support good clinical practice and safe and effective prescribing. Decisions will be taken, at NHS trust level on a case by case basis, based on the needs of the individual patient and the evidence of efficacy and cost effectiveness available.</p><p><strong> </strong></p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy more like this
question first answered
less than 2019-06-11T16:54:00.047Zmore like thismore than 2019-06-11T16:54:00.047Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
1511
label Biography information for Ian Austin more like this